{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 37 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Expedited Reporting of AEs and Drug Exposure During Pregnancy', 'The following must be reported by the investigator on the NIS AE form from signing the', 'informed consent onwards until the end of the study:', 'Type of Report', 'Timeline', 'All Serious Adverse Events (regardless of', 'immediately within 24 hours', 'causality', 'All non-serious ADRs associated with', '7 calendar days', 'nintedanib', 'All pregnancy monitoring forms', '7 calendar days', 'The same timelines apply if follow-up information becomes available for the respective', 'events. In specific occasions the Investigator could inform the Sponsor upfront via telephone.', 'This does not replace the requirement to complete and submit the NIS AE form.', 'Information required', 'For each reportable adverse event, the investigator should provide the information requested', 'on the NIS AE form.', '5.2.6.3', 'Reporting to health authorities', 'Adverse event reporting to regulatory agencies will be done by the MAH according to local', 'and international regulatory requirements.', '5.3', 'DRUG CONCENTRATION MEASUREMENTS AND', 'PHARMACOKINETICS', '5.3.1', 'Assessment of pharmacokinetics', 'Not applicable, there are no pharmacokinetic assessments planned for this trial.', '5.3.2', 'Methods of sample collection', 'Not applicable, there are no pharmacokinetic assessments planned for this trial', '5.3.3', 'Analytical determinations', 'Not applicable, there are no pharmacokinetic assessments planned for this trial.', '5.3.4', 'Pharmacokinetic - pharmacodynamic relationship', 'Not applicable, there are no pharmacokinetic assessments planned for this trial.', '5.4', 'ASSESSMENT OF BIOMARKER(S)', 'Not applicable, there are no biomarker assessments planned in this trial.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 38 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '5.5', 'OTHER ASSESSMENTS', 'No other assessments are planned for this trial.', '5.6', 'APPROPRIATENESS OF MEASUREMENTS', 'All measurements conducted for primary and secondary endpoints are using standard', 'methods.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 39 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '6.', 'INVESTIGATIONAL PLAN', '6.1', 'VISIT SCHEDULE', 'This trial consists of two parts, a screening and an interventional period. The screening period', 'consists of the time between signing consent and randomization, and will last a minimum of 7', 'days. The interventional period consists of the time from randomization through the week 24', 'assessment visit.', 'There are two screening visits (Visit 1, which must be preceded by a separate informed', 'consent Visit 0) and 6 visits (Visits 2 to 7) planned within the 24 week interventional period.', 'There is no follow up period in this trial.', 'After giving his/her informed consent, the patient will be screened for inclusion (see Section', '3.3.2 and exclusion criteria (see Section 3.3.3) for the trial at Visits 0, 1 and Visit 2 (refer to', 'Flowchart).', 'The patient will be dispensed an activity monitor and ProActive tool (eDiary) at the consent', 'visit, and will wear the activity monitor and use the eDiary for 7 days prior to Visit 1 for', 'training purposes.', 'Visit 2 can be performed once the results from local laboratory of Visit 1 are obtained and the', 'patient has worn the activity monitor and completed the eDiary for 7 days. If for any reason', 'the screening phase for an individual patient lasts for more than 6 weeks, then the laboratory', 'examination for Visit 1 has to be repeated before randomization. The patient will be', 'randomized at Visit 2 if all inclusion and none of the exclusion criteria are fulfilled. Central', 'HCRT is not required prior to randomization, but if historical HRCT is not available to be', 'sent for central calculation of QLF, a scan should be obtained after screening/consent at the', 'latest 7 days after Visit 2.', 'On treatment visits will be performed at 3, 6, 12, 18 and 24 weeks. Procedures for these visits', 'are outlined in the flow chart and detailed instructions are available in Section 5, select', 'appendices and the ISF, as applicable.', 'Visit 7 is the end of treatment visit, there is no follow up period. Visit 7 procedures should be', 'followed for early termination visits if possible.', 'If a patient misses a visit, the visit should be rescheduled as soon as possible. If unable to', 'reschedule, the clinical monitor should be contacted.', '01-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}